Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report

Background: Patients with advanced gastric cancer, especially the HER2-positive type, have a poor prognosis; there is a paucity of effective anti-HER2 drug therapies in patients who develop resistance to trastuzumab.Case presentation: We report the case of a 36-year-old male with HER2-positive gastr...

Full description

Bibliographic Details
Main Authors:	Le-Tian Huang, Jie-Tao Ma, Shu-Ling Zhang, Xiao-Han Li, Li Sun, Wei Jing, Jian-Zhu Zhao, Yan-Ru Wang, Cheng-Bo Han
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-12-01
Series:	Frontiers in Oncology
Subjects:	apatinib gastric cancer HER2 nivolumab pyrotinib
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.01453/full

Similar Items

Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib
by: Gao Z, et al.
Published: (2019-04-01)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)

Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
by: Yin Y, et al.
Published: (2020-12-01)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
by: Chaokun Wang, et al.
Published: (2021-05-01)

A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
by: Liu J, et al.
Published: (2021-09-01)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
by: Sun Y, et al.
Published: (2021-09-01)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
by: Yizhao Xie, et al.
Published: (2021-08-01)

Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
by: Zi-yan Yang, et al.
Published: (2020-10-01)

Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report
by: Guo JJ, et al.
Published: (2020-06-01)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2020-05-01)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2021-03-01)

Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review
by: Qu Y, et al.
Published: (2021-03-01)

Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
by: He L, et al.
Published: (2020-08-01)

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
by: Zuhua Chen, et al.
Published: (2020-08-01)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
by: Shan J, et al.
Published: (2020-10-01)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021-08-01)

Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
by: Ding K, et al.
Published: (2021-01-01)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
by: Xinyong Zhang, et al.
Published: (2020-07-01)

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
by: Lili Zhang, et al.
Published: (2021-07-01)

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
by: Changjun Wang, et al.
Published: (2020-07-01)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2021-04-01)

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
by: Hong-Shuai Li, et al.
Published: (2020-10-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
by: Hao Liao, et al.
Published: (2021-05-01)

Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
by: Liu Y, et al.
Published: (2021-06-01)

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
by: Kahraman S, et al.
Published: (2021-07-01)

Role of HER2neu expression in gastric cancer
by: J S Sukanya, et al.
Published: (2021-01-01)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
by: Joseph Tintelnot, et al.
Published: (2020-06-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
by: Xinghao Ai, et al.
Published: (2021-09-01)

Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
by: Siao-Syun Guan, et al.
Published: (2018-06-01)

Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
by: Yanyan Wu, et al.
Published: (2020-07-01)

HER2 status in advanced gastric cancer: the dark side of the moon
by: Antonio Ieni, et al.
Published: (2017-06-01)

Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
by: Zhongben Tang, et al.
Published: (2021-03-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas
by: Indu Rajagopal, et al.
Published: (2015-03-01)

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
by: Hongsik Kim, et al.
Published: (2019-09-01)

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
by: Fu XM, et al.
Published: (2018-09-01)

HER2 expression in gastrointestinal tumor. A focus on diagnostic algorithm of HER2 status from gastric to intestinal cancer
by: I. Panarese, et al.
Published: (2019-03-01)

The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells
by: Li-Fei Sun, et al.
Published: (2020-08-01)